Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets
British Journal of Pharmacology · 2023-10 · 180 (19) · 2455-2481
DOI: 10.1111/bph.16187 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 04.08.2023. Verfasst von Shuxuan Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, Beijing, China. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 133 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Coronavirus disease‐19 (COVID‐19) is caused by severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2) infection. The COVID‐19 pandemic began in March 2020 and has wrought havoc on health and economic systems worldwide. Efficacious treatment for COVID‐19 is lacking: Only preventive measures as well as symptomatic and supportive care are available. Preclinical and clinical studies have indicated that lysosomal cathepsins might contribute to the pathogenesis and disease outcome of COVID‐19. Here, we discuss cutting‐edge evidence on the pathological roles of cathepsins in SARS‐CoV‐2 infection, host immune dysregulations, and the possible underlying mechanisms. Cathepsins are attractive drug targets because of their defined substrate‐binding pockets, which can be exploited as binding sites for pharmaceutical enzyme inhibitors. Accordingly, the potential modulatory strategies of cathepsin activity are discussed. These insights could shed light on the development of cathepsin‐based interventions for COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, Beijing, China.
- Department of Periodontics, Liaoning Provincial Key Laboratory of Oral Diseases, School and Hospital of Stomatology, China Medical University, Shenyang, China.
ORCID-Profile: Junjun Ni
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Zhao, S., Jiang, M., Qing, H., & Ni, J. (2023). Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets. British Journal of Pharmacology, 180(19), 2455-2481. https://doi.org/10.1111/bph.16187
Vancouver
Zhao S, Jiang M, Qing H, Ni J. Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets. British Journal of Pharmacology. 2023;180(19):2455-2481. doi:10.1111/bph.16187
BibTeX
@article{Zhao2023,
author = {Zhao, Shuxuan and Jiang, Muzhou and Qing, Hong and Ni, Junjun},
title = {Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets},
journal = {British Journal of Pharmacology},
year = {2023},
volume = {180},
number = {19},
pages = {2455--2481},
doi = {10.1111/bph.16187}
}
EUVIMED